RxDoctor Payments Data

Yakdan Al Qaisi, MD

Family Medicine · Bakersfield, CANPI 1811068869

Payments from drug & device makers

$320,317in general payments, 2019–2025

Across 45 payments — averaging $7118.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astrazeneca UK Limited$232K
  • AstraZeneca$87K
  • Novartis$99
  • Pfizer$84
  • Novo Nordisk$74
  • Lilly USA, LLC$73
  • plus $442 from 15 others

What the payments were for

  • Food & beverage$772100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$320,317 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$228,521
Medicare patients
112
Services billed
4,552

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide39$41,941
JardianceEmpagliflozin37$39,589
OzempicSemaglutide25$23,573
RybelsusSemaglutide15$19,393
EliquisApixaban30$18,548
JanuviaSitagliptin Phosphate16$18,479
MounjaroTirzepatide16$16,416
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog33$12,073
FarxigaDapagliflozin Propanediol11$11,517
LinzessLinaclotide20$10,664
Janumet XrSitagliptin Phos/Metformin Hcl14$8,254
VascepaIcosapent Ethyl17$7,879
MovantikNaloxegol Oxalate14$5,339
Advair HfaFluticasone Propion/Salmeterol14$4,219
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen160$2,676

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$73$58,35855 claims
Novo NordiskOzempic, Rybelsus$74$42,96640 claims
MerckJanuvia, Janumet Xr$47$26,73230 claims
PfizerEliquis$84$18,54830 claims
AstraZenecaFarxiga$87,232$11,51711 claims
AbbVieLinzess$49$10,66420 claims
GSKArnuity Ellipta$19$2,59711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →